DW recently said NovoSorb was revolutionising the industry. This is with the fully synthetic product, which has far better results and is a lot cheaper than it's competitors. Gaurav Sodhi said on ****** a while back that he sees Polynovo is where Cochlear was 20 years ago. If he is right, Cochlear is a $20b company, why would you want to sell out for $3b if you have a chance of a lot more?
The Clinicians Speak, page-973
-
- There are more pages in this discussion • 49 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.37 |
Change
0.080(3.49%) |
Mkt cap ! $1.635B | |||
| Open | High | Low | Value | Volume |
| $2.35 | $2.44 | $2.31 | $4.848M | 2.032M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 31280 | $2.36 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.38 | 6793 | 3 |
View Market Depth
| Last trade - 16.10pm 16/07/2024 (20 minute delay) ? |
| PNV (ASX) Chart |